AD affects up to 20% of children and 3% of adults and is increasingly common in industrialised countries. AD is characterised by itch (pruritus) which is difficult to control, and inflamed, red skin patches that classically affects the skin creases of the elbows and knees, the scalp and face but can affect any area of the body.
Atopic Dermatitis (AD) or Eczema is a multifactorial disease and its pathophysiology has been linked to (genetic) modification of skin barrier function, bacterial (e.g. Staphylococcus aureus) colonisation and inflammation (Ref 7, 10, 11). It has a lifetime prevalence of 7% (Ref 7).
AD patients complain of dry, inflamed and itchy skin that typically affects the face, inside of the elbows and back of the knees. The current US cost of treatment for atopic dermatitis amounts to $12 billion per year (Ref 7). 75% of the costs are indirect costs e.g. over the counter remedies, lubricants and days lost from work. Such treatments can help in symptom relief but do not tackle the underlying disease. Current second line treatments are topical corticosteroids with third line topical calcineurin inhibitors. These treatments are unpopular because of their significant side effects. What patients and caregivers want is a safe, effective treatment that can be used in all age groups.
Bridge Biotec is developing a new treatment using a potent, selective inhibitor (JEL3108) of one of the key inflammatory pathways in AD. Together with our effective bacteriocidal nanopolymer delivery system this treatment will address two of the three key mechanisms of AD: inflammation and bacterial colonisation.